Single User License
INR 133280
Site License
INR 266560
Corporate User License
INR 399840

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review, H2 2015

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review, H2 2015


  • Products Id :- GMDHC6866IDB
  • |
  • Pages: 112
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Review, H2 2015', provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Non Alcoholic Fatty Liver Disease (NAFLD) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Non Alcoholic Fatty Liver Disease (NAFLD) Overview 9

Therapeutics Development 10

Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD)-Overview 10

Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD)-Comparative Analysis 11

Non Alcoholic Fatty Liver Disease (NAFLD)-Therapeutics under Development by Companies 12

Non Alcoholic Fatty Liver Disease (NAFLD)-Therapeutics under Investigation by Universities/Institutes 14

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Non Alcoholic Fatty Liver Disease (NAFLD)-Products under Development by Companies 18

Non Alcoholic Fatty Liver Disease (NAFLD)-Products under Investigation by Universities/Institutes 20

Non Alcoholic Fatty Liver Disease (NAFLD)-Companies Involved in Therapeutics Development 21

Arisaph Pharmaceuticals, Inc. 21

Conatus Pharmaceuticals Inc. 22

Daewoong Pharmaceutical Co., Ltd. 23

Dimerix Bioscience Pty Ltd 24

Dr. Falk Pharma GmbH 25

DURECT Corporation 26

Galmed International Ltd. 27

Gilead Sciences, Inc. 28

Huons Co., Ltd. 29

Kyorin Pharmaceutical Co., Ltd. 30

Metabolic Solutions Development Company, LLC 31

Novartis AG 32

Raptor Pharmaceuticals Corp. 33

TCM Biotech International Corp 34

Tobira Therapeutics, Inc. 35

Verva Pharmaceuticals Limited 36

Zafgen Inc. 37

Zydus Cadila Healthcare Limited 38

Non Alcoholic Fatty Liver Disease (NAFLD)-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 47

Aramchol-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ARI-3037MO-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

C-10-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

cenicriviroc mesylate-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

cysteamine DR-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

DMX-300-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

DUR-928-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

DWP-10292-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

emricasan-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

HU-002-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

KDT-501-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

MAT-8800-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

MB-12066-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

methazolamide-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

MN-002-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

MSDC-0602-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

norursodeoxycholic acid-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

oltipraz-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

pradigastat sodium-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Px-102-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Px-103-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Px-104-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

saroglitazar-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecules to Activate AMPK for Fatty Liver Disease-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecules to Inhibit NaCT for Metabolic Diseases-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

TCM-606F-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

VVP-100-X-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

ZGN-839-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Non Alcoholic Fatty Liver Disease (NAFLD)-Recent Pipeline Updates 85

Non Alcoholic Fatty Liver Disease (NAFLD)-Dormant Projects 103

Non Alcoholic Fatty Liver Disease (NAFLD)-Product Development Milestones 104

Featured News & Press Releases 104

May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study 104

Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 104

Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 106

Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 107

Mar 26, 2015: Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan 107

Mar 02, 2015: DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 108

Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies 109

Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 110

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2015 10

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD)-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H2 2015 20

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 21

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Conatus Pharmaceuticals Inc., H2 2015 22

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 23

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Dimerix Bioscience Pty Ltd, H2 2015 24

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Dr. Falk Pharma GmbH, H2 2015 25

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by DURECT Corporation, H2 2015 26

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Galmed International Ltd., H2 2015 27

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Gilead Sciences, Inc., H2 2015 28

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Huons Co., Ltd., H2 2015 29

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015 30

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Metabolic Solutions Development Company, LLC, H2 2015 31

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Novartis AG, H2 2015 32

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Raptor Pharmaceuticals Corp., H2 2015 33

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by TCM Biotech International Corp, H2 2015 34

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Tobira Therapeutics, Inc., H2 2015 35

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Verva Pharmaceuticals Limited, H2 2015 36

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Zafgen Inc., H2 2015 37

Non Alcoholic Fatty Liver Disease (NAFLD)-Pipeline by Zydus Cadila Healthcare Limited, H2 2015 38

Assessment by Monotherapy Products, H2 2015 39

Number of Products by Stage and Target, H2 2015 41

Number of Products by Stage and Mechanism of Action, H2 2015 43

Number of Products by Stage and Route of Administration, H2 2015 45

Number of Products by Stage and Molecule Type, H2 2015 46

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics-Recent Pipeline Updates, H2 2015 85

Non Alcoholic Fatty Liver Disease (NAFLD)-Dormant Projects, H2 2015 103

List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2015 10

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD)-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 39

Number of Products by Top 10 Targets, H2 2015 40

Number of Products by Stage and Top 10 Targets, H2 2015 40

Number of Products by Top 10 Mechanism of Actions, H2 2015 42

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 42

Number of Products by Top 10 Routes of Administration, H2 2015 44

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 44

Number of Products by Stage and Top 10 Molecule Types, H2 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Arisaph Pharmaceuticals, Inc.

Conatus Pharmaceuticals Inc.

Daewoong Pharmaceutical Co., Ltd.

Dimerix Bioscience Pty Ltd

Dr. Falk Pharma GmbH

DURECT Corporation

Galmed International Ltd.

Gilead Sciences, Inc.

Huons Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Metabolic Solutions Development Company, LLC

Novartis AG

Raptor Pharmaceuticals Corp.

TCM Biotech International Corp

Tobira Therapeutics, Inc.

Verva Pharmaceuticals Limited

Zafgen Inc.

Zydus Cadila Healthcare Limited

Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutic Products under Development, Key Players in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Overview, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline, Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com